Back to the Top
The following message was posted to: PharmPK
Dear Group,
Please could any one give me a appropriate reference
to quote Talinolo as a P-gp substrate?
Cheers,
CALI
Back to the Top
The following message was posted to: PharmPK
Hi Cali,
there many references quoting talinolol as a P-gp substrate but these
are
few recent ones that might fullfil your inquiry:
1: Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P.
Modulation of drug transport by selected flavonoids: Involvement of P-gp
and OCT?
Eur J Pharm Sci. 2005 Jun;25(2-3):263-71. Epub 2005 Apr 18.
2: Hilgendorf C, Spahn-Langguth H, Rhedin M, Regardh CG, Lowenadler B,
Langguth P. Selective downregulation of the MDR1 gene product in Caco-2
cells by stable transfection to prove its relevance in secretory drug
transport.
Mol Pharm. 2005 Jan-Feb;2(1):64-73.
3: Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J,
Drewe J.
P-glycoprotein and surfactants: effect on intestinal talinolol
absorption.
Clin Pharmacol Ther. 2005 Jan;77(1):24-32.
4: Richter M, Gyemant N, Molnar J, Hilgeroth A.
Comparative effects on intestinal absorption in situ by
P-glycoprotein-modifying HIV protease inhibitors.
Pharm Res. 2004 Oct;21(10):1862-6.
5: Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M,
Dazert
P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W.
Carbamazepine regulates intestinal P-glycoprotein and multidrug
resistance
protein MRP2 and influences disposition of talinolol in humans.
Clin Pharmacol Ther. 2004 Sep;76(3):192-200.
6: El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H,
Langguth
P. Identification of P-glycoprotein substrates and inhibitors among
psychoactive compounds--implications for pharmacokinetics of selected
substrates.
J Pharm Pharmacol. 2004 Aug;56(8):967-75.
7: Ieiri I, Takane H, Otsubo K.
The MDR1 (ABCB1) gene polymorphism and its clinical implications.
Clin Pharmacokinet. 2004;43(9):553-76. Review.
8: Chiou WL, Ma C, Wu TC, Jeong HY.
Unexpected lack of effect of the rifampin-induced P-glycoprotein on the
oral bioavailability of its substrate, talinolol, in humans: implication
in phenotyping.
J Pharm Sci. 2003 Jan;92(1):4-7; discussion 8-9.
9: Deferme S, Mols R, Van Driessche W, Augustijns P
Apricot extract inhibits the P-gp-mediated efflux of talinolol.
J Pharm Sci. 2002 Dec;91(12):2539-48.
10: Deferme S, Van Gelder J, Augustijns P. Inhibitory effect of fruit
extracts on P-glycoprotein-related efflux carriers: an in-vitro
screening.
J Pharm Pharmacol. 2002 Sep;54(9):1213-9.
Kassem Abouchehade
PK/PD Research
School of Pharmacy
Memorial University of Newfoundland
St. John's, NL. A1B 3V6
Back to the Top
The following message was posted to: PharmPK
Dear "Cali",
one good reference for talinolol is "Weitschies et al., Pharm. Res. Vol.
22, No.5, pp. 728ff" and the references stated therein. As the
chacteristic
(Pgp dependent?) phenomenon of double peaks is thoroughly discussed
in this
paper, the possible involvement of further transporters, especially of
uptake transporters comes into place.
best regards,
Philip
Philip Lienau
Schering AG
Research Pharmacokinetics
Tel.: +49 - 30 - 468 - 18507
Fax: +49 - 30 - 468 - 12238
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)